1
|
Castaño-Vinyals G, Sadetzki S, Vermeulen R, Momoli F, Kundi M, Merletti F, Maslanyj M, Calderon C, Wiart J, Lee AK, Taki M, Sim M, Armstrong B, Benke G, Schattner R, Hutter HP, Krewski D, Mohipp C, Ritvo P, Spinelli J, Lacour B, Remen T, Radon K, Weinmann T, Petridou ET, Moschovi M, Pourtsidis A, Oikonomou K, Kanavidis P, Bouka E, Dikshit R, Nagrani R, Chetrit A, Bruchim R, Maule M, Migliore E, Filippini G, Miligi L, Mattioli S, Kojimahara N, Yamaguchi N, Ha M, Choi K, Kromhout H, Goedhart G, 't Mannetje A, Eng A, Langer CE, Alguacil J, Aragonés N, Morales-Suárez-Varela M, Badia F, Albert A, Carretero G, Cardis E. Wireless phone use in childhood and adolescence and neuroepithelial brain tumours: Results from the international MOBI-Kids study. Environ Int 2022; 160:107069. [PMID: 34974237 DOI: 10.1016/j.envint.2021.107069] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 12/22/2021] [Accepted: 12/24/2021] [Indexed: 06/14/2023]
Abstract
In recent decades, the possibility that use of mobile communicating devices, particularly wireless (mobile and cordless) phones, may increase brain tumour risk, has been a concern, particularly given the considerable increase in their use by young people. MOBI-Kids, a 14-country (Australia, Austria, Canada, France, Germany, Greece, India, Israel, Italy, Japan, Korea, the Netherlands, New Zealand, Spain) case-control study, was conducted to evaluate whether wireless phone use (and particularly resulting exposure to radiofrequency (RF) and extremely low frequency (ELF) electromagnetic fields (EMF)) increases risk of brain tumours in young people. Between 2010 and 2015, the study recruited 899 people with brain tumours aged 10 to 24 years old and 1,910 controls (operated for appendicitis) matched to the cases on date of diagnosis, study region and age. Participation rates were 72% for cases and 54% for controls. The mean ages of cases and controls were 16.5 and 16.6 years, respectively; 57% were males. The vast majority of study participants were wireless phones users, even in the youngest age group, and the study included substantial numbers of long-term (over 10 years) users: 22% overall, 51% in the 20-24-year-olds. Most tumours were of the neuroepithelial type (NBT; n = 671), mainly glioma. The odds ratios (OR) of NBT appeared to decrease with increasing time since start of use of wireless phones, cumulative number of calls and cumulative call time, particularly in the 15-19 years old age group. A decreasing trend in ORs was also observed with increasing estimated cumulative RF specific energy and ELF induced current density at the location of the tumour. Further analyses suggest that the large number of ORs below 1 in this study is unlikely to represent an unknown causal preventive effect of mobile phone exposure: they can be at least partially explained by differential recall by proxies and prodromal symptoms affecting phone use before diagnosis of the cases. We cannot rule out, however, residual confounding from sources we did not measure. Overall, our study provides no evidence of a causal association between wireless phone use and brain tumours in young people. However, the sources of bias summarised above prevent us from ruling out a small increased risk.
Collapse
Affiliation(s)
- G Castaño-Vinyals
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - S Sadetzki
- Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Ministry of Health, Jerusalem, Israel
| | - R Vermeulen
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - F Momoli
- School of Epidemiology and Public Health, University of Ottawa, Canada; Risk Science International, Ottawa, Canada
| | - M Kundi
- Department of Environmental Health, Center for Public Health, Medical University Vienna, Austria
| | - F Merletti
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Turin, Italy
| | | | | | - J Wiart
- Laboratoire de Traitement et Communication de l'Information (LTCI), Telecom Paris, Institut Polytechnique de Paris, 91120 Palaiseau, France
| | - A-K Lee
- Radio Technology Research Department, Electronics and Telecommunications Research Institute (ETRI), Yuseong-gu, Daejeon, Korea
| | - M Taki
- Department of Electrical & Electronic Engineering, Graduate Schools of Science and Engineering, Tokyo Metropolitan University, Tokyo, Japan
| | - M Sim
- School of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - B Armstrong
- School of Population and Global Health, The University of Western Australia, Perth 6009, Australia
| | - G Benke
- School of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - R Schattner
- School of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
| | - H-P Hutter
- Department of Environmental Health, Center for Public Health, Medical University Vienna, Austria
| | - D Krewski
- Risk Science International, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada; McLaughlin Centre for Population Health Risk Assessment, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
| | - C Mohipp
- University of Ottawa, Ottawa, Canada
| | - P Ritvo
- York University, Toronto, Ontario, Canada
| | - J Spinelli
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - B Lacour
- French National Registry of Childhood Solid Tumors, CHRU, Nancy, France; Inserm UMR 1153, Center of Research in Epidemiology and StatisticS (CRESS), Paris University, Epidemiology of Childhood and Adolescent Cancers Team (EPICEA), Paris, France
| | - T Remen
- Inserm UMR 1153, Center of Research in Epidemiology and StatisticS (CRESS), Paris University, Epidemiology of Childhood and Adolescent Cancers Team (EPICEA), Paris, France
| | - K Radon
- Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany
| | - T Weinmann
- Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany
| | - E Th Petridou
- Hellenic Society for Social Pediatrics & Health Promotion, Greece; Dept of Hygiene and Epidemiology, Medical School, National and Kapodistrian University of Athens, Greece
| | - M Moschovi
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - A Pourtsidis
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - K Oikonomou
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - P Kanavidis
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - E Bouka
- Hellenic Society for Social Pediatrics & Health Promotion, Greece
| | - R Dikshit
- Centre for Cancer Epidemiology, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India
| | - R Nagrani
- Centre for Cancer Epidemiology, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359 Bremen, Germany
| | - A Chetrit
- Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-Hashomer, Israel
| | - R Bruchim
- Cancer & Radiation Epidemiology Unit, Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Tel-Hashomer, Israel
| | - M Maule
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Turin, Italy
| | - E Migliore
- Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO-Piemonte, Turin, Italy
| | - G Filippini
- Scientific Director's Office, Carlo Besta Foundation and Neurological Institute, Milan, Italy
| | - L Miligi
- Environmental and Occupational Epidemiology Branch, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
| | - S Mattioli
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Italy
| | - N Kojimahara
- Department of Public Health, Tokyo Women's Medical University, Tokyo, Japan; Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan
| | - N Yamaguchi
- Department of Public Health, Tokyo Women's Medical University, Tokyo, Japan; Saiseikai Research Institute of Care and Welfare, Tokyo, Japan
| | - M Ha
- Department of Preventive Medicine, Dankook University College of Medicine, 119 Dandae-ro, Cheonan, Chungnam, South Korea
| | - K Choi
- Department of Preventive Medicine, Dankook University College of Medicine, 119 Dandae-ro, Cheonan, Chungnam, South Korea
| | - H Kromhout
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - G Goedhart
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - A 't Mannetje
- Centre for Public Health Research, Massey University, Wellington, New Zealand
| | - A Eng
- Centre for Public Health Research, Massey University, Wellington, New Zealand
| | - C E Langer
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain
| | - J Alguacil
- CIBER Epidemiologia y Salud Pública, Madrid, Spain; Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - N Aragonés
- CIBER Epidemiologia y Salud Pública, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain
| | - M Morales-Suárez-Varela
- CIBER Epidemiologia y Salud Pública, Madrid, Spain; Unit of Public Health and Environmental Care, Department of Preventive Medicine and Public Health, Food Sciences, Toxicology and Forensic Medicine, University of Valencia, Valencia, Spain
| | - F Badia
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain; Institut Cartogràfic i Geològic de Catalunya, Barcelona, Spain
| | - A Albert
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain
| | - G Carretero
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
| | - E Cardis
- Barcelona Institute of Global Health (ISGlobal), 88 Doctor Aiguader, E-08003 Barcelona, Spain; University Pompeu Fabra, Barcelona, Spain; CIBER Epidemiologia y Salud Pública, Madrid, Spain.
| |
Collapse
|
2
|
Goldberg X, Castaño-Vinyals G, Espinosa A, Carreras A, Liutsko L, Sicuri E, Foraster M, O’Callaghan-Gordo C, Dadvand P, Moncunill G, Dobaño C, Cortés B, Pleguezuelos V, Straif K, Garcia-Aymerich J, de Cid R, Cardis E, Kogevinas M. Mental health and COVID-19 in a general population cohort in Spain (COVICAT study). Soc Psychiatry Psychiatr Epidemiol 2022; 57:2457-2468. [PMID: 35633398 PMCID: PMC9142833 DOI: 10.1007/s00127-022-02303-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 05/05/2022] [Indexed: 11/25/2022]
Abstract
PURPOSE Mental health conditions may affect outcome of COVID-19 disease, while exposure to stressors during the pandemic may impact mental health. The purpose of this study was to examine these factors in relation to ocurrence of depression and anxiety after the first outbreak in Spain. METHODS We contacted 9515 participants from a population-based cohort study in Catalonia between May and October 2020. We drew blood samples to establish infection to the virus. Pre-pandemic mental health conditions were confirmed through Electronic Health Registries. We used the Hospital Anxiety and Depression Scale to assess severe depression and anxiety post-pandemic. Exposure to proximal, financial and wider environment stressors during the lockdown were collected. We calculated Relative Risks (RR), adjusting for individual- and contextual covariates. RESULTS Pre-pandemic mental health disorders were not associated with SARS-CoV-2 infection , but were associated with severity of COVID-19 disease. People with pre-existing mental health disorders showed higher prevalence of severe depression (25.4%) and anxiety (37.8%) than those without prior mental disorders (4.9% and 10.1%). Living alone was a strong predictor of severe depression among mental health patients (RR = 1.6, 95% CI 1.2-2.2). Among those without prior mental health disorders, post-lockdown depression and anxiety were associated with household interpersonal conflicts (RR = 2.6, 95% CI 2.1-3.1; RR = 2.1, 95% CI 1.9-2.4) and financial instability (RR = 2.2, 95% CI 1.8-2.9; 1.9, 95% CI 1.6-2.2). CONCLUSIONS The COVID-19 pandemic and the lockdown were associated with increased post-lockdown depression and anxiety. Patients with pre-existing mental health conditions are a vulnerable group for severe COVID-19 disease.
Collapse
Affiliation(s)
- X. Goldberg
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.488873.80000 0004 6346 3600Mental Health Department, Institut d’Investigació I Innovació Parc Taulí I3PT, Sabadell, Spain ,grid.512890.7CIBER Salud Mental (CIBERSAM), Madrid, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - G. Castaño-Vinyals
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.411142.30000 0004 1767 8811IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
| | - A. Espinosa
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.411142.30000 0004 1767 8811IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
| | - A. Carreras
- grid.429186.00000 0004 1756 6852Genomes for Life-GCAT Lab, Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain
| | - L. Liutsko
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain ,grid.412761.70000 0004 0645 736XUrFU, Yekaterinburg, Russia
| | - E. Sicuri
- grid.410458.c0000 0000 9635 9413ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
| | - M. Foraster
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain ,grid.6162.30000 0001 2174 6723PHAGEX Research Group, Universitat Ramon Llull, Blanquerna School of Health Science, Barcelona, Spain
| | - C. O’Callaghan-Gordo
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain ,grid.36083.3e0000 0001 2171 6620Universitat Oberta de Catalunya, Barcelona, Spain
| | - P. Dadvand
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
| | - G. Moncunill
- grid.410458.c0000 0000 9635 9413ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
| | - C. Dobaño
- grid.410458.c0000 0000 9635 9413ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
| | - B. Cortés
- grid.429186.00000 0004 1756 6852Genomes for Life-GCAT Lab, Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain
| | | | - K. Straif
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.208226.c0000 0004 0444 7053Boston College, Chestnut Hill, MA USA
| | - J. Garcia-Aymerich
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
| | - R. de Cid
- grid.429186.00000 0004 1756 6852Genomes for Life-GCAT Lab, Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain
| | - E. Cardis
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.411142.30000 0004 1767 8811IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
| | - M. Kogevinas
- grid.434607.20000 0004 1763 3517ISGlobal, Barcelona, Spain, Barcelona, Spain ,grid.411142.30000 0004 1767 8811IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ,grid.5612.00000 0001 2172 2676Universitat Pompeu Fabra (UPF), Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
| |
Collapse
|
3
|
Pinto-Carbó M, Peiró-Pérez R, Molina-Barceló A, Vanaclocha-Espi M, Alguacil J, Castaño-Vinyals G, O’Callaghan-Gordo C, Gràcia-Lavedan E, Pérez-Gómez B, Lope V, Aragonés N, Molina AJ, Fernández-Villa T, Gil-Majuelo L, Amiano P, Dierssen-Sotos T, Gómez-Acebo I, Guevara M, Moreno-Iribas C, Obón-Santacana M, Rodríguez-Suárez MM, Salcedo-Bellido I, Delgado-Parrilla A, Marcos-Gragera R, Chirlaque MD, Kogevinas M, Pollán M, Salas D. Social mobility and healthy behaviours from a gender perspective in the Spanish multicase-control study (MCC-Spain). PLoS One 2021; 16:e0251447. [PMID: 33979362 PMCID: PMC8115806 DOI: 10.1371/journal.pone.0251447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 04/26/2021] [Indexed: 11/19/2022] Open
Abstract
There is evidence for the influence of socioeconomic status (SES) on healthy behaviours but the effect of social mobility (SM) is not yet well known. This study aims to analyse the influence of origin and destination SES (O-SES and D-SES) and SM on healthy behaviours and co-occurrence, from an integrated gender and age perspective. Data were obtained from the controls of MCC-Spain between 2008-2013 (3,606 participants). Healthy behaviours considered: healthy diet, moderate alcohol consumption, non-smoking and physical activity. SM was categorized as stable high, upward, stable medium, downward or stable low. Binary and multinomial logistic regression models were adjusted. Those aged <65, with a low O-SES, D-SES and stable low SM are less likely to have healthy behaviours in the case of both women (physically active: OR = 0.65 CI = 0.45-0.94, OR = 0.71 CI = 0.52-0.98, OR = 0.61 CI = 0.41-0.91) and men (non-smokers: OR = 0.44 CI = 0.26-0.76, OR = 0.54 CI = 0.35-0.83, OR = 0.41 CI 0.24-0.72; physically active: OR = 0.57 CI = 0.35-0.92, OR = 0.64 CI = 0.44-0.95, OR = 0.53 CI = 0.23-0.87). However, for those aged ≥65, this probability is higher in women with a low O-SES and D-SES (non-smoker: OR = 8.09 CI = 4.18-15.67, OR = 4.14 CI = 2.28-7.52; moderate alcohol consumption: OR = 3.00 CI = 1.45-6.24, OR = 2.83 CI = 1.49-5.37) and in men with a stable low SM (physically active: OR = 1.52 CI = 1.02-1.26). In the case of men, the same behaviour pattern is observed in those with a low O-SES as those with upward mobility, with a higher probability of co-occurring behaviours (three-to-four behaviours: OR = 2.00 CI = 1.22-3.29; OR = 3.13 CI = 1.31-7.48). The relationship of O-SES, D-SES and SM with healthy behaviours is complex and differs according to age and gender.
Collapse
Affiliation(s)
- M. Pinto-Carbó
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
| | - R. Peiró-Pérez
- Inequalities Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
- General Directorate of Public Health, Valencia, Valencian Community, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
| | - A. Molina-Barceló
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
| | - M. Vanaclocha-Espi
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
| | - J. Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Centre for Health and Environmental Research, Huelva University, Huelva, Andalucia, Spain
| | - G. Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain
| | - C. O’Callaghan-Gordo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain
- Faculty of Health Science,Universitat Oberta de Catalunya, Barcelona, Catalonia, Spain
| | - E. Gràcia-Lavedan
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain
| | - B. Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - V. Lope
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - N. Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - A. J. Molina
- The Research Group in Gene—Environment and Health Interactions, Institute of Biomedicine (IBIOMED), University of León, León, Castilla y León, Spain
| | - T. Fernández-Villa
- The Research Group in Gene—Environment and Health Interactions, Institute of Biomedicine (IBIOMED), University of León, León, Castilla y León, Spain
| | - L. Gil-Majuelo
- Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Gipuzkoa, Spain
- Biodonostia Health Research Institute, Group of Epidemiology of Chronic and Communicable Diseases, San Sebastián, Gipuzkoa, Spain
| | - P. Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Gipuzkoa, Spain
- Biodonostia Health Research Institute, Group of Epidemiology of Chronic and Communicable Diseases, San Sebastián, Gipuzkoa, Spain
| | - T. Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Cantabria University, Santander, Cantabria, Spain
| | - I. Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Cantabria University, Santander, Cantabria, Spain
| | - M. Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Navarra, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain
| | - C. Moreno-Iribas
- Navarra Public Health Institute, Pamplona, Navarra, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain
| | - M. Obón-Santacana
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Barcelona, Catalonia, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - M. M. Rodríguez-Suárez
- Preventive Medicine and Public Health Area, Oviedo University, Oviedo, Asturias, Spain
- Central University Hospital of Asturias, Public Health Service of the Principe de Asturias, Oviedo, Asturias, Spain
| | - I. Salcedo-Bellido
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Andalucia, Spain
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Andalucia, Spain
| | - A. Delgado-Parrilla
- Centre for Health and Environmental Research, Huelva University, Huelva, Andalucia, Spain
| | - R. Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Catalonia, Spain
- Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute], Girona, Catalonia, Spain
| | - M. D. Chirlaque
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, El Palmar, Murcia, Spain
| | - M. Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain
| | - M. Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - D. Salas
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
- General Directorate of Public Health, Valencia, Valencian Community, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
| |
Collapse
|
4
|
Solans M, Coenders G, Marcos-Gragera R, Castelló A, Gràcia-Lavedan E, Benavente Y, Moreno V, Pérez-Gómez B, Amiano P, Fernández-Villa T, Guevara M, Gómez-Acebo I, Fernández-Tardón G, Vanaclocha-Espi M, Chirlaque MD, Capelo R, Barrios R, Aragonés N, Molinuevo A, Vitelli-Storelli F, Castilla J, Dierssen-Sotos T, Castaño-Vinyals G, Kogevinas M, Pollán M, Saez M. Compositional analysis of dietary patterns. Stat Methods Med Res 2018; 28:2834-2847. [PMID: 30045678 DOI: 10.1177/0962280218790110] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Instead of looking at individual nutrients or foods, dietary pattern analysis has emerged as a promising approach to examine the relationship between diet and health outcomes. Despite dietary patterns being compositional (i.e. usually a higher intake of some foods implies that less of other foods are being consumed), compositional data analysis has not yet been applied in this setting. We describe three compositional data analysis approaches (compositional principal component analysis, balances and principal balances) that enable the extraction of dietary patterns by using control subjects from the Spanish multicase-control (MCC-Spain) study. In particular, principal balances overcome the limitations of purely data-driven or investigator-driven methods and present dietary patterns as trade-offs between eating more of some foods and less of others.
Collapse
Affiliation(s)
- M Solans
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain.,3 Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | - G Coenders
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain
| | - R Marcos-Gragera
- 2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain.,3 Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | - A Castelló
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,4 Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,5 Faculty of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
| | - E Gràcia-Lavedan
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,6 ISGlobal, Barcelona, Spain.,7 ISGlobal, Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Y Benavente
- 8 Unit of molecular and genetic epidemiology in infections and cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - V Moreno
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,9 Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.,10 Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL). Hospitalet de Llobregat, Barcelona, Spain.,11 Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - B Pérez-Gómez
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,12 Cardiovascular and Metabolic Diseases Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - P Amiano
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,13 Public Health Division of Gipuzkoa, BioDonostia Research Institute, Health Department, Basque Country, San Sebastian, Spain
| | | | - M Guevara
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,15 Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - I Gómez-Acebo
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,16 Universidad de Cantabria - IDIVAL, Santander, Spain
| | - G Fernández-Tardón
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,17 IUOPA, Universidad de Oviedo, Asturias, Spain
| | - M Vanaclocha-Espi
- 18 Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain
| | - M D Chirlaque
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,19 Department of Epidemiology, Regional Health Authority, IMIB-Arrixaca, Murcia University, Murcia, Spain
| | - R Capelo
- 20 Centro de Investigación en Recursos Naturales, Salud y medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - R Barrios
- 21 Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad de Granada, Granada, Spain
| | - N Aragonés
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,22 Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - A Molinuevo
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | | | - J Castilla
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,15 Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - T Dierssen-Sotos
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,16 Universidad de Cantabria - IDIVAL, Santander, Spain
| | - G Castaño-Vinyals
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,6 ISGlobal, Barcelona, Spain.,7 ISGlobal, Universitat Pompeu Fabra (UPF), Barcelona, Spain.,23 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - M Kogevinas
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,6 ISGlobal, Barcelona, Spain.,7 ISGlobal, Universitat Pompeu Fabra (UPF), Barcelona, Spain.,23 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - M Pollán
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,4 Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - M Saez
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain
| |
Collapse
|
5
|
Pollán M, Lope V, Castelló A, Mena-Bravo A, Amiano P, Aragonés N, Fernández-Villa T, Guevara M, Dierssen T, Fernández-Tardón G, Castaño-Vinyals G, Marcos-Grajera R, Moreno V, Salas-Trejo D, Díaz-Santos M, Kogevinas M, Pérez-Gómez B, Priego-Capote F. Abstract P3-09-01: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- M Pollán
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - V Lope
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - A Castelló
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - A Mena-Bravo
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - P Amiano
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - N Aragonés
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - T Fernández-Villa
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - M Guevara
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - T Dierssen
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - G Fernández-Tardón
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - G Castaño-Vinyals
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - R Marcos-Grajera
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - V Moreno
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - D Salas-Trejo
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - M Díaz-Santos
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - M Kogevinas
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - B Pérez-Gómez
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| | - F Priego-Capote
- National Center for Epidemiology; Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Madrid, Spain; University of Córdoba, Córdoba, Spain; 4Public Health Division of Gipuzkoa, BioDonostia Research Institute, Sam Sebastian, Guipuzcoa, Spain; University of León, Institute of Biomedicine (IBIOMED), León, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Navarra, Spain; University of Cantabria—IDIVAL, Santander, Cantabria, Spain; IUOPA University of Oviedo, Oviedo, Asturias, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Epidemiology Unit & Girona Cancer Registry, Oncology Coordination Plan, Autonomous Government of Catalonia, Girona, Spain; IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; 12Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunid
| |
Collapse
|
6
|
Vermeulen SH, Hanum N, Grotenhuis AJ, Castaño-Vinyals G, van der Heijden AG, Aben KK, Mysorekar IU, Kiemeney LA. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer 2014; 112:594-600. [PMID: 25429525 PMCID: PMC4453642 DOI: 10.1038/bjc.2014.601] [Citation(s) in RCA: 63] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Revised: 10/27/2014] [Accepted: 11/02/2014] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Controversy exists on whether urinary tract infection (UTI) is a risk factor for urinary bladder cancer (UBC). Here, the association is investigated using data from one of the largest bladder cancer case-control studies worldwide. METHODS Information on (i) history and age at onset of regular cystitis ('regular low-UTI') and (ii) number and age at onset of UTI treated with antibiotics ('UTI-ab') from 1809 UBC patients and 4370 controls was analysed. Odds ratios (ORs) and 95% confidence intervals (CI) adjusted for age, education, smoking, and use of aspirin/ibuprofen were generated, for men and women separately. RESULTS Regular low-UTI was associated with an increased UBC risk (men: OR (95% CI) 6.6 (4.2-11); women: 2.7 (2.0-3.5)), with stronger effects in muscle-invasive UBC. Statistically significant decreased risks (ORs ∼0.65) were observed for up to five UTI-ab, specifically in those who (had) smoked and experienced UTI-ab at a younger age. In women, UTI experienced after menopause was associated with a higher UBC risk, irrespective of the number of episodes. CONCLUSIONS Regular cystitis is positively associated with UBC risk. In contrast, a limited number of episodes of UTI treated with antibiotics is associated with decreased UBC risk, but not in never-smokers and postmenopausal women.
Collapse
Affiliation(s)
- S H Vermeulen
- Department for Health Evidence & Department of Human Genetics, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - N Hanum
- Department for Health Evidence, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - A J Grotenhuis
- Department for Health Evidence, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - G Castaño-Vinyals
- Centre for Research in Environmental Epidemiology (CREAL), Doctor Aiguader 88, E-08003 Barcelona, Spain
| | - A G van der Heijden
- Department of Urology, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| | - K K Aben
- 1] Department for Health Evidence, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands [2] Comprehensive Cancer Centre the Netherlands, 3511 GD Utrecht, The Netherlands
| | - I U Mysorekar
- Departments of Obstetrics & Gynecology, Pathology & Immunology, Washington University School of Medicine, 660S. Euclid Avenue, St. Louis MO 63110, USA
| | - L A Kiemeney
- Department for Health Evidence & Department of Urology, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands
| |
Collapse
|
7
|
Serra C, Kogevinas M, Silverman DT, Turuguet D, Tardon A, Garcia-Closas R, Carrato A, Castaño-Vinyals G, Fernandez F, Stewart P, Benavides FG, Gonzalez S, Serra A, Rothman N, Malats N, Dosemeci M. Work in the textile industry in Spain and bladder cancer. Occup Environ Med 2007; 65:552-9. [PMID: 18045847 DOI: 10.1136/oem.2007.035667] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND/OBJECTIVE Textile manufacturing is a complex industry that has frequently been associated with bladder cancer. However, results have not been consistent. This study investigated the risk of bladder cancer in Spanish textile workers. METHODS We analysed data from a multicentre hospital-based case-control study carried out in Spain (1998-2001) including 1219 cases of bladder cancer and 1271 controls. Of those, 126 cases and 122 controls reported a history of employment in the textile industry. Lifetime occupational history was obtained using a computer-assisted personal interview. Occupations, locations and materials used in the textile industry were assessed using a detailed questionnaire and expert assessment. RESULTS Overall, no increased risk of bladder cancer was found for textile workers, including duration of employment analysis. Increased risks were observed for weavers (OR = 1.82, 95% CI 0.95 to 3.47), for workers in winding/warping/sizing (OR 4.11, 95% CI 1.58 to 10.71) and for those exposed to synthetic materials (OR 1.89, 95% CI 1.00 to 3.56). Working for more than 10 years appeared to be associated with an increased risk for weavers (OR 2.27, 95% CI 0.97 to 5.34), for those who had ever worked in winding/warping/sizing (OR 11.03, 95% CI 1.37, 88.89), for workers in the weaving room (OR 2.94, 95% CI 1.24 to 7.01) and for those exposed to synthetic (OR 2.62, 95% CI 1.14 to 6.01) or cotton (OR 2.00, 95% CI 1.04 to 3.87) materials. Statistically significant higher risks were also found for specific combinations of occupations or locations with exposure to synthetics and cotton. CONCLUSIONS There was no overall increased risk for textile workers, but increased risks were found for specific groups of workers. Our findings indicate that observed risks in previous studies may be better evaluated by analysis of materials used or section worked within the industry and occupation.
Collapse
Affiliation(s)
- C Serra
- Unit of Occupational Health Research, University Pompeu Fabra, PRBB Building, 1st floor room 171.01, C/Dr Aiguader, 88, 08003-Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
Among the scientific interests of cancer epidemiology is the identification of both environmental and genetic factors associated with cancer development. Observational designs requiring sophisticated methodology are applied to control for potential confounding factors. The enormous biotechnological potential developed in the last two decades has allowed the integration of a plethora of new biomarkers in epidemiological studies to better define the exposure and "neoclassic" outcomes, as well as incorporating genetic susceptibility factors in both classical and new epidemiological designs. The integration of scopes, objectives, data and tools coming from different disciplines also benefits epidemiology, thus evolving into "systems epidemiology". In this manuscript, we review the basic concepts of study designs and data analysis and introduce readers to the more innovative aspects that are now being applied in epidemiological studies.
Collapse
Affiliation(s)
- N Malats
- Centre de Recerca en Epidemiologia Ambiental, Institut Municipal d'Investigació Mèdica, Barcelona, Spain.
| | | |
Collapse
|
9
|
Pennanen AS, Sillanpää M, Hillamo R, Quass U, John AC, Branis M, Hůnová I, Meliefste K, Janssen NAH, Koskentalo T, Castaño-Vinyals G, Bouso L, Chalbot MC, Kavouras IG, Salonen RO. Performance of a high-volume cascade impactor in six European urban environments: mass measurement and chemical characterization of size-segregated particulate samples. Sci Total Environ 2007; 374:297-310. [PMID: 17287015 DOI: 10.1016/j.scitotenv.2007.01.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2006] [Revised: 12/15/2006] [Accepted: 01/02/2007] [Indexed: 05/13/2023]
Abstract
The performance of a modified Harvard high-volume cascade impactor (HVCI) was evaluated in six field campaigns with size-segregated particulate samplings for chemical and toxicological characterization. The 7-week sampling campaigns in 2002-2003 in Duisburg (autumn), Prague (winter), Amsterdam (winter), Helsinki (spring), Barcelona (spring), and Athens (summer) were selected to represent contrasting urban environments and seasons of public health interest due to high particulate concentrations or previous findings in epidemiological studies. Particulate samples were collected in parallel with the HVCI (PM(10-2.5), PM(2.5-1), PM(1-0.2), PM(0.2)), a virtual impactor (VI; PM(10-2.5), PM(2.5)), and a Berner low-pressure impactor (BLPI; 10 stages between 0.035 and 10 mum in particle diameter) using a 3- or 4-day sampling duration. The campaigns exhibited different profiles with regard to particulate mass concentration, size distribution, chemical composition and meteorological conditions, thus providing a demanding setup for an overall field comparison of the HVCI with the VI and BLPI reference samplers. Size-segregated particulate mass concentration could be reasonably well measured with the present HVCI configuration. The coarse (PM(10-2.5)) and fine (PM(2.5)) particulate mass agreed within 10% with the low-volume reference samplers, and the four-stage size distribution of the HVCI followed the modal pattern of urban aerosol. The concentrations of chemical constituents measured and integrated especially for the HVCI-PM(2.5) differed to some extent from those measured from the corresponding VI-PM(2.5) samples. This implies that when investigating the association of toxicological responses with the chemical constituents of particulate matter, it is necessary to use the chemical composition data of the same samples as used in toxicological experiments.
Collapse
Affiliation(s)
- A S Pennanen
- National Public Health Institute (KTL), Department of Environmental Health, PO Box 95, FI-70701 Kuopio, Finland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Villanueva CM, Cantor KP, Grimalt JO, Castaño-Vinyals G, Malats N, Silverman D, Tardon A, Garcia-Closas R, Serra C, Carrato A, Rothman N, Real FX, Dosemeci M, Kogevinas M. Assessment of lifetime exposure to trihalomethanes through different routes. Occup Environ Med 2006; 63:273-7. [PMID: 16556748 PMCID: PMC2078091 DOI: 10.1136/oem.2005.023069] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/20/2006] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To evaluate lifetime exposure to trihalomethanes (THM) through ingestion, inhalation, and dermal absorption in a hospital based case-control study of bladder cancer conducted between 1998 and 2001 in five areas of Spain. The study base was comprised of subjects living in the catchment areas of the participating hospitals. METHODS Individual information on water related habits was obtained from personal interviews of 1219 cases and 1271 controls: residential and occupational history, drinking water source at each residence and job, amount of water consumption, frequency and duration of showering, bathing, and swimming pool attendance. THM levels, water source history, and year when chlorination started in study areas were ascertained through measurements in drinking water samples and questionnaires to water companies and local authorities. Estimates of THM levels covered 79% of the subjects' person-years of exposure. RESULTS Current and historical average THM levels in water were correlated. Control subjects reported that drinking water source in the last residence was municipal for 63%, bottled for 22%, private well for 2%, and other sources for 13%. For the time window between age 15 and the time of interview, average residential THM level was 32.2 mug/l. THM exposure through ingestion was 23.7 mug/day on average, and was correlated with the ingestion THM level in the workplace. Overall, 79% usually took showers, 16% usually took baths, and 13% had ever attended a swimming pool. Between 21% and 45% of controls unexposed to THM through ingestion were evaluated as moderately or highly exposed through showering or bathing, and 5-10% were exposed through swimming in pools. CONCLUSION The importance of evaluating different routes is underscored by findings from experimental studies showing substantial differences in THM uptake and internal distribution by route.
Collapse
Affiliation(s)
- C M Villanueva
- Respiratory and Environmental Health Research Unit, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Castaño-Vinyals G, D'Errico A, Malats N, Kogevinas M. Biomarkers of exposure to polycyclic aromatic hydrocarbons from environmental air pollution. Occup Environ Med 2004; 61:e12. [PMID: 15031403 PMCID: PMC1740739 DOI: 10.1136/oem.2003.008375] [Citation(s) in RCA: 130] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Metabolites of pyrene and DNA adducts have been used as biomarkers of high level exposure to polycyclic aromatic hydrocarbons (PAHs). A systematic review was performed to evaluate whether these biomarkers are also valid markers of low level environmental exposure to PAHs. Thirty five studies were identified with more than 10 subjects that evaluated environmental air pollution to PAHs in relation to metabolites of PAHs, mainly hydroxypyrene (1-OHP), PAH-DNA adducts, or protein adducts. PAH metabolites and, to a less extent, PAH-DNA adducts correlated well at the group level with exposure to B(a)P even at low levels of air pollution. The use of these biomarkers should be more widely implemented in combination with more traditional techniques for the assessment of general population exposure to PAHs from ambient air pollution.
Collapse
Affiliation(s)
- G Castaño-Vinyals
- Respiratory and Environmental Research Unit, Municipal Institute of Medical Research, Barcelona, Spain
| | | | | | | |
Collapse
|